Bristol-Myers Squibb (NY:BMY)

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline ↗

September 30, 2024

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company...

Via Benzinga

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

September 30, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

NYSE:BMY Shows Potential for a Breakout. ↗

September 23, 2024

A technical analysis of BRISTOL-MYERS SQUIBB CO (NYSE:BMY) shows it may be setting up for a breakout.

Via Chartmill

What Analysts Are Saying About Bristol-Myers Squibb Stock ↗

September 16, 2024

Via Benzinga

Current Report: Bristol-Meyers Squibb (BMY) ↗

September 16, 2024

The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout!

Via Talk Markets

3 Surprisingly Underrated Stocks to Buy Right Now ↗

September 28, 2024

These stocks might look like bad picks. But appearances can be deceiving.

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

September 27, 2024

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential ↗

September 27, 2024

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...

Via Benzinga

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

September 27, 2024

The Fed's preferred inflation gauge, the PCE Price Index, rose 2.2% YoY, below expectations. Decline in overall inflation suggests an easing of price pressures.

14 Stocks Gain Momentum As August Inflation Comes In Below Expectations ↗

September 27, 2024

Via Benzinga

Topics Economy

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades ↗

September 27, 2024

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without...

Via Benzinga

Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗

September 27, 2024

Via Benzinga

Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market ↗

September 27, 2024

Sentiment has soured ahead of the key inflation data that is due ahead of the market open on Friday, with the index futures pointing to a modestly lower opening.

Via Benzinga

Topics Economy

Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout ↗

September 26, 2024

Cobenfy is the first drug to treat the disorder without blocking dopamine.

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ↗

September 25, 2024

2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval...

Via Benzinga

Analysts Think There's Still Time to Get in on Edgewise, Up 332%

September 25, 2024

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years ↗

September 20, 2024

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...

Via Benzinga

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗

September 19, 2024

Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy ↗

September 18, 2024

Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.

Via Benzinga

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

September 18, 2024

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗

September 16, 2024

Now could be a great time to scoop up three stocks trading way below their previous peaks.

The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.

Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗

September 15, 2024

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

September 15, 2024

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

September 14, 2024